MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202611060105 A) filed by Noida Institute Of Engineering Technology Pharmacy Institute on May 12, 2026, for A Pharmaceutical Composition For Controlled Enzyme Inhibition.
Inventors include Dr. Anjna Rani; and Dr. Swarupanjali Padhi.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: A pharmaceutical composition for controlled enzyme inhibition comprises an inhibitor containing core, a protective carrier phase, a release rate controlling phase, and a modulation phase arranged to regulate local availability of an enzyme inhibiting active ingredient. The composition stabilizes the inhibitor, limits premature exposure, and provides a selected release profile through a target exposure interface. The formulation may be configured as tablets, pellets, films, depots, or other dosage forms and supports reproducible enzyme modulation by correlating release behavior with functional inhibition response.
Disclaimer: Curated by HT Syndication.
